A research team from Helmholtz Munich and the Technical University of Munich has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater efficiency than before. Their technology, ENVLPE, uses engineered non-infectious virus-like particles to precisely correct defective genes – demonstrated successfully in living mouse models that are blind due to a mutation. This system also holds promise for advancing cancer therapy by enabling precise genetic manipulation of engineered immune cells making them more universally compatible and thus more accessible for a larger group of cancer patients.